EP3301105B1 - Neue oleanan-24-ester verbindungen zur behandlung von krebs und anderen krankheiten - Google Patents

Neue oleanan-24-ester verbindungen zur behandlung von krebs und anderen krankheiten Download PDF

Info

Publication number
EP3301105B1
EP3301105B1 EP17191658.8A EP17191658A EP3301105B1 EP 3301105 B1 EP3301105 B1 EP 3301105B1 EP 17191658 A EP17191658 A EP 17191658A EP 3301105 B1 EP3301105 B1 EP 3301105B1
Authority
EP
European Patent Office
Prior art keywords
cancer
tig
compound
moderate
benzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17191658.8A
Other languages
English (en)
French (fr)
Other versions
EP3301105A1 (de
Inventor
Pui-Kwong Chan
May Sung Mak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacific Arrow Ltd
Original Assignee
Pacific Arrow Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/042240 external-priority patent/WO2011009032A1/en
Priority claimed from US12/856,322 external-priority patent/US8586719B2/en
Application filed by Pacific Arrow Ltd filed Critical Pacific Arrow Ltd
Publication of EP3301105A1 publication Critical patent/EP3301105A1/de
Application granted granted Critical
Publication of EP3301105B1 publication Critical patent/EP3301105B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Definitions

  • This invention provides compounds, compositions and compounds for inhibiting cancer invasion, cell invasion, or cancer cell invasion.
  • This invention provides methods of synthesing new compounds for pharmaceutical uses.
  • This invention provides methods, compounds and compositions for treating cancer, inhibiting cancer invasion, cell invasion, or cancer cell invasion, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers.
  • This invention provides compounds, compositions, and compounds for treating cancer, inhibiting cancer invasion, cell invasion, cancer cell invasion, and metastasis.
  • This invention provides a use of compounds, compositions, for manufacturing medicament for treating cancer, inhibiting cancer invasion, and metastasis.
  • This invention provides compounds for use as mediator or inhibitor of adhesion protein or angiopoietin,
  • This invention provides compounds for use in a method of modulating attachment or adhesion of cells or angiogenesis, by modulating or inhibiting adhesion protein or angiopoietin,
  • the compounds comprise the structures selected from the formulae as specified in the claims, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers.
  • This invention provides these compounds for use as a mediator
  • This invention provides compounds for use in anti adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor.
  • This invention provides compounds or a composition comprising the compounds provided in the invention for treating cancers; for inhibiting cancer growth, for inhibiting viruses; for preventing cerebral aging; for improving memory; improving cerebral functions; for curing enuresis, frequent micturition, urinary incontinence; dementia, Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions; for treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder; cerebrovascular diseasea; inhibiting NF-Kappa B activation; for treating brain edema, severe acute respiratory syndrome, respiratory viral diseases, chronic venous insufficiency, hypertension, chronic venous disease, oedema, inflammation, hemonhoids, peripheral edema formation, varicose vein disease, flu, post traumatic edema and postoperative swelling; for inhibiting blood clots, for inhibiting ethanol absorption; for
  • This invention provides a composition for AntiMS, antianeurysm, antiasthmatic, anti-oedematous, anti-inflammatory, antibradykinic, anticapillarihemorrhagic, anticephalagic, anticervicobrachialgic, antieclamptic, antiedemic, antiencaphalitic, antiepiglottitic, antiexudative, antiflu, antifracture, antigingivitic, antihematomic, antiherpetic, antihistaminic, antihydrathritic, antimeningitic, antioxidant, antiperiodontic, antiphlebitic, antipleuritic, antiraucedo, antirhinitic, antitonsilitic, antiulcer, antivaricose, antivertiginous, cancerostatic, corticosterogenic, diuretic, fungicide, hemolytic, hyaluronidase inhibitor, lymphagogue, natriuretic, pesticide, pituitary stimulant, thymolytic, vaso
  • This invention provides compounds, compositions and compounds for treating cancer diseases, inhibiting cancer invasion, for inhibiting cancer growth or for inhibiting cancer metastasis, wherein the compounds comprise the structures selected from the formulae specified in the claims, wherein the cancers comprise breast cancer, leukocytic cancer, liver cancer, ovarian cancer, bladder cancer, prostatic cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphhatic cancer, pancreatic cancer, stomach cancer and thyroid cancer; wherein the cells comprise breast cell, leukocytic cell, liver cell, ovarian cell, bladder cell, prostatic cell, skin cell, bone cell, brain cell, leukemia cell, lung cell, colon cell, CNS cell, melanoma cell, renal cell, cervical cell, esophageal cell, testicular cell, spleenic cell, kidney cell, lymphhatic cell
  • This invention shows that the presence of Tigloyl, angeloyl, Crotonoyl, senecioyl, Cinnamoyl, Pentenoyl, Hexanoyl, benzoyl, Ethylbutyryl, at a pentacyclic triterpene, triterpene, triterpeniod, triterpeniod saponin or compound selected from formulae as specified in the claims, produces inhbition of cancer growth, cancer invasion, cells invasion, cancer cell invasion, cell adhesion, cell circulation or cell attachment.
  • This invention shows that the presence of Tigloyl, angeloyl, Crotonoyl, senecioyl, Cinnamoyl, Pentenoyl, Hexanoyl, benzoyl, Ethylbutyryl, in the compounds of the formulae as specified in the claims, produces inhibition of cancer growth, cancer invasion, cells invasion or cancer cell invasion.
  • the presence of group(s) selected from Tigloyl, angeloyl, Crotonoyl, senecioyl, Cinnamoyl, Pentenoyl, Hexanoyl, benzoyl, Ethylbutyryl, in the compounds of the formulae as specified in the claims produces activities including inhibition of cancer growth, cancer invasion, cells invasion, cancer cell invasion, cell adhesion, cell attachment or cell circulating.
  • the compounds provided in the invention are for treating cancers, inhibition of cancer growth, cancer invasion, cells invasion, cancer cell invasion; cell adhesion, cell attachment, cell circulating; for inhibiting viruses; for preventing cerebral aging; for improving memory; improving cerebral functions; for curing enuresis, frequent micturition, urinary incontinence; dementia, Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions; for treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder; cerebrovascular diseasea; inhibiting NF-Kappa B activation; for treating brain edema, severe acute respiratory syndrome, respiratory viral diseases, chronic venous insufficiency, hypertension, chronic venous disease, oedema, inflammation, hemonhoids, peripheral edema formation, varicose vein disease, flu, post traumatic edema and postoperative swelling; for inhibiting blood clo
  • This invention provides a composition for AntiMS, antianeurysm, antiasthmatic, anti-oedematous, anti-inflammatory, antibradykinic, anticapillarihemorrhagic, anticephalagic, anticervicobrachialgic, antieclamptic, antiedemic, antiencaphalitic, antiepiglottitic, antiexudative, antiflu, antifracture, antigingivitic, antihematomic, antiherpetic, antihistaminic, antihydrathritic, antimeningitic, antioxidant, antiperiodontic, antiphlebitic, antipleuritic, antiraucedo, antirhinitic, antitonsilitic, antiulcer, antivaricose, antivertiginous, cancerostatic, corticosterogenic, diuretic, fungicide, hemolytic, hyaluronidase inhibitor, lymphagogue, natriuretic, pesticide, pituitary stimulant, thymolytic, vaso
  • AKOH has no effect in inhibiting cancer growth, cancer invasion, cells invasion or cancer cell invasion.
  • AKOH was obtained by removing the angeloyl groups from carbon positions 21 and 22 of the active Xanifolia Y(Y3).
  • This invention shows that the ability for inhibiting cancer invasion, cells invasion or cancer cell invasion of Xanifolia Y(Y3) are lost by removing angeloyl groups from carbon positions 21 and 22.
  • the core compound including E4A, E5A, Xanifolia Y-core have no effect in inhibiting cancer growth, cancer invasion, cells invasion or cancer cell invasion.
  • Xanifolia Y-core was obtained by removing the angeloyl groups from carbon positions 21 and 22, and the sugar moieties from carbon 3 of the active Xanifolia Y(Y3).
  • E4A (E IV A) was obtained by removing the groups from carbon positions 3, 21 and 22 of the active Escin.
  • E5A (E V A) was obtained by removing the groups from carbon positions 3, 21 and 22 of the active Escin.
  • the core compound including E4A, E5A, Xanifolia Y-core and AKOH have no hemolytic activity and anti cancer activity.
  • Tig-N, Tig -Q, Tig -R, Tig-T Tig-S and Tig-V do not have hemolytic activity up to 20 ug/ml.
  • the original compound ES lyse 100% red blood cells (RBC) at 5 ug/ml. Compare to Y3, the ACH-Y3 is less potent in hemolytic activity.
  • Tig-R has no hemolytic activity.
  • Tig-N, Tig -Q, Tig -R, Tig-T Tig-S and Tig-V have anti cancer activities.
  • This disclosure shows that the ability for inhibiting cancer growth, cancer invasion, cells invasion or cancer cell invasion are maintained when the sugar moieties are removed from carbon position 3 of an active compound, triterpene, triterpeniod, or triterpeniod saponin.
  • the compound ACH-Y3 has the ability to inhibit cancer invasion, cells invasion or cancer cell invasion.
  • the compound ACH-Y3 was obtained by removing the sugar moieties from carbon position 3 of a active Xanifolia Y(Y3).
  • This disclosure shows that the ability for inhibiting cancer invasion, cells invasion or cancer cell invasion are maintained when the sugar moieties are removed from the carbon position 3 of active Xanifolia Y(Y3).
  • a compound which has bio-activities including inhibiting cancer growth, inhibiting cancer invasion, cells invasion or cancer cell invasion is called active compound.
  • This invention provides compounds for treating cancers, inhibition of cancer growth, cancer invasion, cells invasion, cancer cell invasion; cell adhesion, cell attachment, cell circulating, or for inhibiting cancer metastasis, wherein the compounds comprise the structures selected from the formulae as specified in the claims, wherein the compounds can be synthesized or isolated, wherein the cells comprise cancer cells, wherein the cancers comprise breast cancer, leukocytic cancer, liver cancer, ovarian cancer, bladder cancer, prostatic cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphhatic cancer, pancreatic cancer, stomach cancer and thyroid cancer.
  • the method of inhibiting cancer invasion, cells invasion or cancer cell invasion activities uses non-cytotoxic drug concentrations.
  • the method of inhibiting metastasis uses non-cytotoxic drug concentrations. There is no noticeable change in cell morphology.
  • This invention provides the compounds of the formulae as specified in the claims, for treating cancers, inhibition of cancer growth, cancer invasion, cells invasion, cancer cell invasion; cell adhesion, cell attachment, cell circulating, migration, metastasis or growth of cancers, wherein the methods comprise affecting gene expression, wherein the methods comprise stimulating gene expression, or wherein the methods comprise inhibiting the gene expression, or wherein the methods comprise administering to a subject an effective amount of compounds, compositions in this application.
  • the selected compound binds to the adhesive proteins (by masking) on the membrane and inhibits the interaction of adhesion proteins with their receptors.
  • the selected compound's action on the membrane affects adhesion proteins' function in the membrane. The lost of adhesion activity of cancer cells is result from direct or indirect action of the selected compound on membrane proteins.
  • This invention provides the compounds as specified in the claims per se and also for use in methods for inhibiting cancer invasion, cell invasion, cancer cell invasion, migration, metastasis or growth of cancers, wherein this invention comprises a process and method for administration of the composition, wherein administration is by intravenous injection, intravenous drip, intraperitoneal injection or oral administration; wherein administration is by intravenous drip: 0.003-0.03mg/kg body weight of compound dissolved in 250ml of 10% glucose solution or in 250ml of 0.9% NaCl solution, or by intravenous injection: 0.003-0.03mg/kg body weight per day of compound dissolved in 10-20ml of 10% glucose solution or of 0.9% NaCl solution, or 0.01-0.03mg/kg body weight of compound dissolved in 250ml of 10% glucose solution or in 250ml of 0.9% NaCl solution, or by intravenous injection: 0.01-0.03mg/kg body weight per day of compound dissolved in 10-20ml of 10% glucose solution or of 0.9% NaCl solution, or 0.01-
  • This invention provides the compounds as specified in the claims per se and also for use in methods for treating cancers, inhibition of cancer growth, cancer invasion, cells invasion, cancer cell invasion; cell adhesion, cell attachment, cell circulating, migration, metastasis or growth of cancers, wherein the invention comprises a pharmaceutical composition comprising the compound of this invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent, wherein said compound is present in a concentration of 0.01 ug/ml to 65ug/ml, or wherein said compound is present in a concentration of 0.01 ug/ml to 40ug/ml, or wherein said compound is present in a concentration of 0.01 ug/ml to 30ug/ml, or wherein said compound is present in a concentration of 0.01ug/ml to 10ug/ml, or wherein said compound is present in a concentration of 0.01ug/ml to 5ug/ml, or wherein said compound is present in a concentration of 5ug/
  • This invention provides the compounds as specified in the claims per se and also for use in methods for treating cancers, inhibition of cancer growth, cancer invasion, cells invasion, cancer cell invasion; cell adhesion, cell attachment, cell circulating, migration, metastasis or growth of cancers, wherein the invention comprises a pharmaceutical composition comprising the compound of this invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent, wherein said compound is present in a concentration of 0.008uM to 80uM, or wherein said compound is present in a concentration of 0.01uM to 60uM, or wherein said compound is present in a concentration of 0.01uM to 50uM, or wherein said compound is present in a concentration of 0.01uM to 40uM, or wherein said compound is present in a concentration of 0.01uM to 30uM, or wherein said compound is present in a concentration of 0.01uM to 20uM, or wherein said compound is present in a concentration of 0.01uM to 10uM, or wherein said compound is
  • said compound is present in a concentration of 7uM to 8uM, or wherein said compound is present in a concentration of 7uM to 10uM, or wherein said compound is present in a concentration of 7uM to 15uM, or wherein said compound is present in a concentration of 7uM to 20uM, or wherein said compound is present in a concentration of 7uM to 30uM or wherein said compound is present in a concentration of 7uM to 40uM, or wherein said compound is present in a concentration of 7uM to 50uM or wherein said compound is present in a concentration of 7uM to 60uM, or wherein said compound is present in a concentration of 7uM to 80uM.
  • the active compound, cellulose, and a portion of the corn starch are mixed and granulated to 10% corn starch paste.
  • the resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate.
  • the resulting granulation is then compressed into tablets containing 1, 5, 10, 20, 30mg, respectively of active ingredient per tablet.
  • An intravenous dosage form of the active compound is prepared as follows:
  • the active compound is dissolved at room temperature in a prepared solution of sodium chloride, citric acid, and sodium citrate in water for injection.
  • Intravenous drip preparation 1-2.mg compound dissolved in 250ml of 10% glucose solution or in 250ml of 0.9% NaCl solution
  • angelic acid Treatment of angelic acid with one of the many standard chlorinating reagents including phosphorus ocychloride, phosphorus trichloride and thionyl chloride produces tigloyl chloride.
  • Oxalyl chloride produces a 2:1 ratio of angeloyl chloride to tigloyl chloride.
  • Treatment of potassium salt in diethyl ether with oxalyl chloride and catalytic DMF for 2 hr at 0C produces pure angeloyl chloride.
  • composition comprises bioactive compounds from natural plants or synthesis.
  • the program is based on our purification methods and biological assays including the MTT assay. See International Application No. PCT/US05/31900, filed September 7, 2005 , U.S. Serial No. 11/289142, filed November 28, 2005 , and U.S. Serial No. 11/131551, filed May 17, 2005 , and PCT/US2008/002086 , 1188-ALA-PCT, filed February 15, 2008, 12/344,682, 1020-B1-US, filed December 29, 2008.
  • Erythrocytes were isolated from human blood (EDTA whole blood, collected randomly). 50ul of the 10% RBC suspension (in PBS) was added to 2 ml of sample solutions (concentration range from 0.1 ug/ml to 400 ug/ml) in PBS. The mixture was vortexed briefly and sat for 60 min at room temperature. The mixture was spun at 3K for 10 min and the relative amounts of lysed hemoglobin in the supernatant were measured at 540 nm. The synthetic compounds of present application were tested with this method.
  • Compounds AKOH-Y and AKOH-M10 do not show the ability to inhibit cancer growth, cancer invasion, cells invasion or cancer cell invasion.
  • a core compound or pentacyclic triterpenes, hydroxylated triterpenes is obtained by acid and alkaline hydroysis of saponin from natural sources.
  • a pentacyclic triterpene can also be obtained by synthetic methods.
  • a method for synthesizing the core compound is as follows: Beta-Escin, compound Y, Y10, Y2, Y8, Y7, Y0, X, or M10 dissolved in 1M NaOH (20 mg/ml) was incubated at 70C for 5 hours. The hydrolyzed solution was neutralized with HCl and the water was evaporated by lyophilization. The product was dissolved in 50% methanol and 1N HCl. The mixture was incubated at 70C for 5 hours.
  • the core compounds do not show the ability to inhibit cancer growth, cancer invasion, or cell adhesion.
  • core compounds also named as bES-core, , E IV A, ES4A, E4A or (E); also named as ES V, E5A or (F) wherein R1, R2, R5, R8 represent OH; R3 represents OH, H or absent; R4, R10 represent CH3 or CH2OH; R9, R11, R12, R13, R14, R15 represent CH3; wherein R1, R2, R5, R8, R17, R18 represent OH; R3 represents OH, H or absent; R9, R11, R12, R13, R14, R15 represent CH3.
  • R1, R2, R5, R8, R17, R18 represent OH;
  • R9, R11, R12, R13, R14, R15 represent CH3, also named E4A or (E).
  • a method of attaching functional groups to the core compounds involves esterification of core compounds with acyl chloride including but not limited to Tigloyl chloride, angeloyl chloride, Acetyl chloride, Crotonoyl chloride, 3,3-Dimethylartyloyl chloride, senecioyl chloride, Cinnamoyl chloride, Pentenoyl chloride, Hexanoyl chloride, benzoyl chloride or Ethylbutyryl chloride for 5 sec, 1 min, 2 min, 5 min, 10 min, 30 min, 1hr, 2 hr, 18 hr, 2 days or 3 days at 0C, 25C or 75C temperature.
  • acyl chloride including but not limited to Tigloyl chloride, angeloyl chloride, Acetyl chloride, Crotonoyl chloride, 3,3-Dimethylartyloyl chloride, senecioyl chloride, Cinnamoyl chloride,
  • the reaction product is dissolved in 80% acetonitrile - 0.005% Trifluoroacetic acid.
  • the active esterification products are purified with HPLC. MTT activity was performed to test the activity of acyl chloride, solution after the reaction, individual fractions, and individual compounds.
  • the core compounds are synthetic, semi synthetic or from natural source. The core compounds are including terpene, isoprene, triterpenes, and hydroxylated triterpenes.
  • the peaks, fractions and compounds are selected according to the activities of times studies and the changes of peaks. Selecting the HPLC fractions for isolation is according to the cytotoxic activity of the reaction product obtained at a specific time. The compounds having strong to weak activities are selected and isolated.
  • the anti cancer activities are the MTT studies of bone (U2OS), lung (H460), bladder(HTB-9), ovary (ES2), colon (HCT116), pancreas (Capan), ovary(OVCAR3), prostate (DU145), skin (SK-Mel-5), mouth (KB), kidney (A498), breast (MCF-7), liver (HepG2), brain (T98G), luekemia (K562), cervix (HeLa).
  • acyl chloride including Tigloyl chloride, angeloyl chloride, Acetyl chloride, Crotonoyl chloride, 3,3-Dimethylartyloyl chloride, senecioyl chloride, Cinnamoyl chloride, Pentenoyl chloride, Hexanoyl chloride, benzoyl chloride or Ethylbutyryl chloride
  • acyl chloride including Tigloyl chloride, angeloyl chloride, Acetyl chloride, Crotonoyl chloride, 3,3-Dimethylartyloyl chloride, senecioyl chloride, Cinnamoyl chloride, Pentenoyl chloride, Hexanoyl chloride, benzoyl chloride or Ethylbutyryl chloride
  • the compounds vary in composition when the time or temperature of the reaction is changed.
  • the peaks, fractions and compounds are selected according to the activities of times studies and the changes of peaks.
  • the anti cancer activities are the MTT studies of bone (U2OS), lung (H460), bladder(HTB-9), ovary (ES2), colon (HCT116), pancreas (Capan), ovary(OVCAR3), prostate (DU145), skin (SK-Mel-5), mouth (KB), kidney (A498), breast (MCF-7), liver (HepG2), brain (T98G), luekemia (K562), cervix (HeLa).
  • the active esterification products are purified with HPLC.
  • the reaction product of mixtures and individual compounds are tested with MTT Cytotoxic Assay. Details of method are in Experiment 3 of the present application.
  • a second esterification of compound can be selected from the above experiment results to produce new active compounds.
  • a partial esterification compound is selected from the above experiments to perform a second or repeated with a third esterification with different acyl chloride in order to produce new active compounds with the experiments in the present application.
  • a method is 1) Dissolving core compound or triterpenes core, hydroxylated triterpenes core in pyridine; 2) Adding acyl chloride; 3, The mixture is stirred for length of time including 5 sec, 1 min, 2 min, 5 min, 10 min, 30 min, 1 hr, 2 hr, 18 hr, 2 days or 3 days at different temperature; 4) At the end of reaction, aqueous solution of acid or weak base, or water is added to the reaction mixture; 5) The solution is then extracted of ethyl acetate and lyophilization; 6) Dissolving the reaction product in acetonitrile with Trifluoroacetic acid or DMSO; 7) Testing the reaction product of mixtures and individual fractions with MTT cytotoxic assay; 8) Selecting the HPLC fractions for isolation is according to the cytotoxic activity of the reaction product obtained at a specific reaction time; 10) Purifiing the active esterification products with HPLC; 11) Collecting the products; 12) Testing the products
  • IC50 of bone is 4.5 ug/ml
  • lung H460
  • bladder(HTB-9) is 2.5 ug/ml
  • ovary ES2
  • colon HCT116
  • pancreas Capan
  • ovary(OVCAR3) is 5.8, prostate (DU145) is 3.6 ug/ml
  • skin SK-Mel-5) is 5.1ug/ml
  • mouth KB
  • kidney A498) is 3.5 ug/ml
  • breast (MCF-7) is 4.5 ug/ml
  • liver HepG2
  • brain T98G
  • leukemia K562
  • cervix HLa
  • IC50 of bone is 7 ug/ml
  • lung H460
  • bladder(HTB-9) is 4 ug/ml
  • ovary ES2
  • colon is 8 ug/ml
  • pancreas Capan 5 ug/ml
  • ovary(OVCAR3) is 9
  • prostate DU145
  • skin SK-Mel-5
  • mouth KB
  • kidney A4908
  • breast (MCF-7) is 9 ug/ml
  • liver HepG2
  • brain T98G
  • leukemia K562
  • cervix HeLa
  • IC50 of bone is 15 ug/ml
  • lung H460
  • bladder(HTB-9) is 7.5 ug/ml
  • ovary ES2
  • colon is 15 ug/ml
  • pancreas Capan 8 ug/ml
  • ovary(OVCAR3) is 18, prostate (DU145) is 4.8 ug/ml
  • skin SK-Mel-5) is 15 ug/ml
  • mouth (KB) is 9 ug/ml
  • kidney A498)
  • breast MCF-7) is 13 ug/ml
  • liver HepG2
  • brain T98G
  • leukemia K562
  • cervix HeLa
  • IC50 of bone is 20 ug/ml
  • lung H460
  • bladder(HTB-9) is 10 ug/ml
  • ovary ES2
  • colon is 22 ug/ml
  • pancreas Capan 9 ug/ml
  • ovary(OVCAR3) is 23
  • prostate DU145
  • skin SK-Mel-5)
  • mouth KB
  • kidney A498)
  • breast MCF-7) is 18 ug/ml
  • liver HepG2 is 24 ug/ml
  • brain T98G
  • leukemia K562
  • cervix HeLa
  • IC50 of bone is 20 ug/ml
  • lung H460
  • bladder HLB-9
  • ovary ES2
  • colon HCT116
  • pancreas Capan 10 ug/ml
  • ovary(OVCAR3) 25
  • prostate DU145
  • skin SK-Mel-5
  • mouth KB
  • kidney A498)
  • breast MCF-7
  • liver HepG2
  • brain T98G
  • leukemia K562
  • cervix is 18 ug/ml.
  • IC50 of bone is 23 ug/ml
  • lung H460
  • bladder(HTB-9) is 15 ug/ml
  • ovary ES2
  • colon is 26 ug/ml
  • pancreas Capan 9 ug/ml
  • ovary(OVCAR3) is 27, prostate (DU145) is 15 ug/ml
  • skin SK-Mel-5) is 24ug/ml
  • mouth (KB) is 16 ug/ml
  • kidney (A498) is 18 ug/ml
  • breast (MCF-7) is 25 ug/ml
  • liver HepG2
  • brain T98G
  • leukemia K562
  • cervix HeLa
  • a compound for the manufacture of a medicament or uses of a compound for medicament selected from formula (2A), for treating cancer, inhibiting cancer growth, inhibiting cancer invasion, inhibiting cancer metastasis, modulating cell adhesion, modulating cell attachment, using compounds selected from the following:
  • a composition comprising an effective amount of compound selected from the above formula or a salt, ester, metabolite or derivative thereof can be used as a medicament for blocking the invasion, migration, metastasis of cancer cells, inhibiting tumor or cancer cell growth and for treating cancer, wherein the cancers comprise breast cancer, leukocytic cancer, liver cancer, ovarian cancer, bladder cancer, prostatic cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer, spleenic cancer, kidney cancer, lymphhatic cancer, pancreatic cancer, stomach cancer and thyroid cancer.
  • the cancers comprise breast cancer, leukocytic cancer, liver cancer, ovarian cancer, bladder cancer, prostatic cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer, cervical cancer, esophageal cancer, testicular cancer,
  • This invention provides a composition comprising the compounds specified in the claims for treating cancers; for inhibiting viruses; for preventing cerebral aging; for improving memory; improving cerebral functions; for curing enuresis, frequent micturition, urinary incontinence; dementia, Alzheimer's disease, autism, brain trauma, Parkinson's disease or other diseases caused by cerebral dysfunctions; for treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder; cerebrovascular diseasea; inhibiting NF-Kappa B activation; for treating brain edema, severe acute respiratory syndrome, respiratory viral diseases, chronic venous insufficiency, hypertension, chronic venous disease, oedema, inflammation, hemonhoids, peripheral edema formation, varicose vein disease, flu, post traumatic edema and postoperative swelling; for inhibiting blood clots, for inhibiting ethanol absorption; for lowering blood sugar; for regulating
  • This invention provides a composition for AntiMS, antianeurysm, antiasthmatic, anti-oedematous, anti-inflammatory, antibradykinic, anticapillarihemorrhagic, anticephalagic, anticervicobrachialgic, antieclamptic, antiedemic, antiencaphalitic, antiepiglottitic, antiexudative, antiflu, antifracture, antigingivitic, antihematomic, antiherpetic, antihistaminic, antihydrathritic, antimeningitic, antioxidant, antiperiodontic, antiphlebitic, antipleuritic, antiraucedo, antirhinitic, antitonsilitic, antiulcer, antivaricose, antivertiginous, cancerostatic, corticosterogenic, diuretic, fungicide, hemolytic, hyaluronidase inhibitor, lymphagogue, natriuretic, pesticide, pituitary stimulant, thymolytic, vaso
  • alkenyl groups include vinyl, propenyl, isopropenyl, butenyl, s- and t-butenyl, pentenyl, hexenyl, butadienyl, pentadienyl, and hexadienyl.
  • An aryl is a functional group of organic molecule derived from an aromatic compound such as benzene, a 6-14 membered carbocyclic aromatic ring system comprising 1-3 benzene rings. If two or more aromatic rings are present, then the rings are fused together, so that adjacent rings share a common bond. Examples include phenyl and naphthyl.
  • the aryl group may be substituted with one or more substitutes independently selected from halogen, alkyl or alkoxy.
  • Acyl is a functional group which can be obtained from an organic acid by the removal of the carboxyl.
  • Acyl groups can be written using the general formula -COR, where there is a double bond between the carbon and oxygen.
  • the names of acyl groups typically end in -yl, such as formyl, acetyl, propionyl, butyryl and benzoyl.
  • Benzoyl is one of the acyls, C 6 H 5 COR, obtained from benzoic acid by the removal of the carboxyl.
  • a heterocyclic compound is a compound containing a heterocyclic ring which refers to a non-aromatic ring having 1-4 heteroatoms, said ring being isolated or fused to a second ring selected from 3- to 7-membered alicyclic ring containing 0-4 heteroatoms, aryl and heteroaryl , wherein heterocyclic compounds include pyrrolidinyl , pipyrazinyl , morpholinyl, trahydrofuranyl, imidazolinyl, thiomorpholinyl, and the like.
  • Heterocyclyl groups are derived from heteroarenes by removal of a hydrogen atom from any ring atom.
  • Alkanoyl is the general name for an organic functional group RCO-, where R represents hydrogen or an alkyl group. Examples of alkanoyls are acetyl, propionoyl, butyryl, isobutyryl, pentanoyl and hexanoyl.
  • Alkenoyl is an alkenylcarbonyl in which the alkenyl is defined above. Examples are pentenoyl(tigloyl) and hexenoyl(angeloyl).
  • Alkyl is a radical containing only carbon and hydrogen atoms arranged in a chain, branched, cyclic or bicyclic structure or their combinations, having 1-18 carbon atoms. Examples include but are not limited to methyl, ethyl, propyl isopropyl, butyl, s- and t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • Benzoyl alkyl substituted alkanoyl refers to straight or branched alkanoyl substituted with at least one benzoyl and at least one alkyl, wherein the benzoyl is attached to a straight or branched alkyl.
  • An example of a benzoyl alkyl substituted alkanoyl is benzoyl methyl isobutanoyl.
  • a sugar moiety is a segment of molecule comprising one or more sugars or derivatives thereof or alduronic acid thereof.
  • Isobutyryl is a synonym of 2-Methylpropanoyl (Y)Y3, Y and Y3 represent the same compound.
  • YM and (ACH-Y) represent the same compound.
  • Connecting moiety is a substructure or a group of atoms which connect the functional group to a core compound.
  • angeloyl group is connected by a sugar moiety to a triterpene core.
  • the building blocks used herein including triterpenes, hydroxylated triterpenes, acetyl, angeloyl, tigloyl, senecioyl, Crotonoyl, 0-3,3-Dimethylartyloyl, Cinnamoyl, Pentenoyl, Hexanoyl, benzoyl, Ethylbutyryl, alkyl, dibenzoyl, benzoyl, methylbutanoyl, methylpropanoyl, alkanoyl, alkenoyl, benzoyl alkyl substituted alkanoyl, alkanoyl substituted phenyl, alkenoyl substituted phenyl, aryl, acyl, heterocylic, heteroraryl, alkenylcarbonyl, acetyl chloride, angeloyl chloride, tigloyl chloride, senecioyl chloride, Crotonoy
  • concentrations of drug that inhibit 15% cell-growth or less (i.e. 85% of control or above) as compared to the no-drug control (DMSO) are considered non-cytotoxic concentrations.
  • concentrations of drug that inhibit 10% cell-growth or less (i.e. 90% of control or above) as compared to the no-drug control (DMSO) are considered non-cytotoxic concentrations.
  • concentrations of drug that inhibit 5% cell-growth or less (i.e. 95% of control or above) as compared to the no-drug control (DMSO) are considered non-cytotoxic concentrations.
  • concentrations of drug that inhibit 20% cell-growth or less i.e.
  • the concentrations of drug that inhibit 25% cell-growth or less (i.e. 75% of control or above) as compared to the no-drug control (DMSO) are considered non-cytotoxic concentrations.
  • the concentrations of drug that inhibit 30% cell-growth or less as compared to the no-drug control (DMSO) are considered non-cytotoxic concentrations.
  • the concentrations of drug that inhibit 45% cell-growth or less as compared to the no-drug control (DMSO) are considered non-cytotoxic concentrations.
  • the triterpene compound or compounds selected from this invention as defined in the claims can be administered to a subject in need thereof, treating the subject, wherein including preventing cancer, or providing an adjuvant effect to the subject, or inhibiting the initation or promotion of cancer, or killing the cancer/tumor cells, or inhibiting cancer cell invasion.
  • the compounds inhibit the activation of nuclear factor-kB, wherein inhibiting the localization or wherein binding the DNA.
  • the compounds induce apoptosis in cancer cells.
  • the Real-time PCR results confirmed that Compound Y3 and YM increase the expression of the genes: ANGPT2, DDIT3, LIF and NFKB1Z, wherein the results in Table 19-21 disclosed in PCT/US09/34115, filed February 13, 2009 are incorporated herein by reference.
  • the saponins are partially hydrolyzed into a mixture of products which can be separated by HPLC. Specific partial hydrolysis of saponins can also be achieved with enzymes.
  • the glycosidases catalyze the hydrolysis of the glycosidic linkage.
  • Galactosidase is an enzyme which catalyzes the hydrolysis of galactosides.
  • Glucosidase is an enzyme which breaks glucose from saponin.
  • xylanases lactase, amylase, chitinase, sucrase, maltase, and neuraminidase.
  • the sugar moiety of the triterpenoid saponin (example Xanifolia Y) can be removed by acid hydrolysis.
  • the synthetic compound of ACH-Y is obtained.
  • ACH-Y is a triterpene with acyl groups but no sugar moiety.
  • the acyl group of the saponin (example Xanifolia Y) can be removed by alkaline hydrolysis.
  • the synthetic compound AKOH-Y can be obtained.
  • AKOH-Y is a pentacyclic triterpene with sugar moieties.
  • a pentacyclic triterpene can be obtained by acid and alkaline hydroysis of saponins from natural sources.
  • a pentacyclic triterpene can be obtained by synthetic methods (Reference: Surendra et al., Rapid and Enantioselective Synthetic Approches to Germanicol and Other Pentacyclic Triterpenes, Journal of the American Chemical Society, 2008, 130(27), 8865-8869 ).
  • Pentacyclic triterpenes with sugar moieties can also be obtained by synthesis ( Reference: Ple et al., Synthesis of L-arabinopyranose containing hederagenin saponins, Tetrahedron 61 (2005) 4347-4362 ).
  • Acylation is the process of adding an acyl group to a compound.
  • the Friedel-Crafts reaction is an example of this process.
  • An active compound can be obtained by acylating a pentacyclic triterpenes, or hydroxylated triterpenes.
  • acylating C24, C28, C21 and C22 of a pentacyclic triterpenes, or hydroxylated triterpenes produce compounds for inhibiting cancer growth, cancer invasion, cell invasion, cancer cell invasion, cell attachment adhesion, or cell circulation.
  • the acyl group(s) may be at C3.
  • a sugar moiety is at C21, 22, or 28, wherein the sugar moiety is attached with 2 acyl groups.
  • acylating the compounds of (A), (B), (C), (D), (F), (G), (H), produce the compounds for inhibiting cancer invasion, cells invasion or cancer cell invasion; cancer metastasis; or cancer growth
  • the building blocks in the present application are used to synthesise active saponins.
  • Applicant further states that anti adhesion therapy and targeting adhesion molecules for therapy is a new direction for development of drugs.
  • Some examples of anti-adhesion drugs in clinical trials are Efalizumab, Odulimomab, Alicaforsen, Aselizumab etc, which target varies adhesion proteins. Please see TEXT BOOK, Adhesion Molecules: Function and Inhibition, (Reference 2), edited by Klaus Ley page 289-291, 297 .
  • Adhesion molecules in inflammatory disease (Reference 4), Abstract, line 7-8 "Blockade of the function of expression of CAM has emerged as a new therapeutic target in inflammatory diseases".
  • Applicants' invention is an anti adhesion therapy which is a new use of the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment.
  • compounds selected from structure (2A) for anti adhesion therapy as a mediator or inhibitor of adhesion proteins and angiopoietins, and modulation of the cell attachment, and cell adhesion.
  • the mixture is stirred for 5 sec, 1 min, 2 min, 5 min, 10 min, 30 min, 1 hr, 2 hr, 18 hr, 2 days or 3 days at 0C, 25C or 75C temperature.
  • 5 ml of 2N HCl or 1M NaHCO3 is added to the reaction mixture.
  • the solution is then extracted 3 times with 10 ml of ethyl acetate which is then evaporated under vacuum and at 45C and lyophilization.
  • the reaction product is dissolved in 80% acetonitrile - 0.005% Trifluoroacetic acid or DMSO; and was separated with HPLC. Selecting the HPLC fractions for isolation is according to the cytotoxic activity of the reaction product obtained at a specific reaction time.
  • the active esterification products are purified with HPLC.
  • the reaction product of mixtures and individual compounds are tested with MTT cytotoxic assay. See examples Figures 1-12
  • HTB-9 (bladder), HeLa-S3 (cervix), DU145 (prostate), H460 (lung), MCF-7 (breast), K562 (leukemia), HCT116 (colon), HepG2 (liver), U2OS (bone), T98G (brain), SK-MEL-5 (Skin) and OVCAR 3, ES2 (ovary), Pancreas(Capan), Mouth(KB), Kidney(A498).
  • MTT Assay The procedure for MTT assay followed the method described by Carmichael et al.(1987) with modifications.
  • the cells were seeded into a 96-well plate at for 24 hours before drug-treatment.
  • the cells were then exposed to the drugs for 48, 72, or 96 hours.
  • MTT 0.5 mg/mL
  • the formazan product of the reduction of tetrazolium by viable cells
  • the MTT level of the cells before drug-treatment was also measured (T0).
  • %G (TD-T0 / TC-T0) x 100(1), where TC or TD represents O.D. readings of control or drug-treated cells.
  • LC cytotoxicity
  • E4A-Tig-R Chemical synthesis of E4A-Tig-R: 1. Preparation of E4A; 2. Esterification of E4A with Tigloyl Chloride; 3. Isolation of E4A-Tig-N with HPLC Cytotoxic activity determination: 1. MTT assay Chemical structure determination: 1. NMR analysis; 2. Mass Spectrum analysis
  • E4A-Tig-R Chemical synthesis of E4A-Tig-R: 1. Preparation of E4A; 2. Esterification of E4A with Tigloyl Chloride; 3. Isolation of E4A-Tig-Q with HPLC Cytotoxic activity determination: 1. MTT assay Chemical structure determination: 1. NMR analysis; 2. Mass Spectrum analysis
  • E4A-Tig-V Chemical synthesis of E4A-Tig-V: 1. Preparation of E4A; 2. Esterification of E4A with Tigloyl Chloride; 3. Isolation of E4A-Tig-V with HPLC Cytotoxic activity determination: 1. MTT assay Chemical structure determination: 1. NMR analysis; 2. Mass Spectrum analysis
  • E4A-Tig-T Chemical synthesis of E4A-Tig-T: 1. Preparation of E4A; 2. Esterification of E4A with Tigloyl Chloride; 3. Isolation of E4A-Tig-T with HPLC Cytotoxic activity determination: 1. MTT assay Chemical structure determination: 1. NMR analysis; 2. Mass Spectrum analysis
  • E4A-Tig-S Chemical synthesis of E4A-Tig-S: 1. Preparation of E4A; 2. Esterification of E4A with Tigloyl Chloride; 3. Isolation of E4A-Tig-S with HPLC Cytotoxic activity determination: 1. MTT assay Chemical structure determination: 1. NMR analysis; 2. Mass Spectrum analysis
  • E4A-Tig-S Chemical synthesis of E4A-Tig-S: 1. Preparation of E4A; 2. Esterification of E4A with Tigloyl Chloride; 3. Isolation of E4A-Tig-S with HPLC Cytotoxic activity determination: 1. MTT assay Chemical structure determination: 1. NMR analysis; 2. Mass Spectrum analysis
  • Experiment 15 Using method in Experiment 8, esterification of E4A with acetyl, angeloyl, tigloyl, senecioyl, Crotonoyl, Cinnamoyl, Pentenoyl, Hexanoyl, Ethylbutyryl, gave the following compounds
  • Experiment 17 Esterification of E4A-Tig-N with angeloyl chloride, Acetyl chloride, Crotonoyl chloride, 3,3-Dimethylartyloyl chloride, senecioyl chloride, Cinnamoyl chloride, Pentenoyl chloride, Hexanoyl chloride, benzoyl chloride or Ethylbutyryl chloride; Isolation with HPLC; Cytotoxic activity determination; Chemical structure determination with the method of Experiment 8, gave the following compounds:
  • ES2 or Hey8A cells were plated in T25 flasks with medium containing 5 ug/ml of compounds selected from structure (2A) including E4A-Tig-R, E4A-Tig-V, E4A-Tig-S, E4A-Tig-N, E4A-Tig-Q, E4A-Tig-T. Cultures were incubated for 5 hours. Attached cells were removed from flasks by trypsinization and the amounts were counted. Compare to no drug controls, 80 ⁇ 4 % of ES2 cells and 60 ⁇ 4 % of Hey8A cells were found attached to flasks under this condition.
  • Western blot is applied in this invention as a method to detect the specific proteins in treated and untreated cells with compounds in this invention, wherein the cells are bladder, cervix, prostate, lung, breast, leukemia, colon, liver, bone, brain, Skin, ovary, Pancreas(Capan), Mouth(KB), Kidney
  • Cells targeted cells were grown in RPMI 1640 medium. 1.5 million cells were seeded in a T25 flask and grown for 24 hours before drug-treatment.
  • Drug-treatment Cells cultures were replaced with fresh RPMI medium containing either 2.5 ul of DMSO (as control) [D]; or 10, 20, 30, 40, 80 ug/ml of tested compounds. After 24 hours, aliquot of culture medium was taken out for Fibronectin determination (Western blot method).
  • Results show that compounds of E4A-Tig-R, E4A-Tig-V, E4A-Tig-S, E4A-Tig-N, E4A-Tig-Q, E4A-Tig-T inhibit fibronectin secretion from 20-40%.in bladder, cervix, prostate, lung, breast, leukemia, colon, liver, bone, brain, Skin, ovary, Pancreas(Capan), Mouth(KB), Kidney. Table 1: Table.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Claims (15)

  1. Eine Verbindung der Formel
    Figure imgb0097
     oder ein pharmazeutisch verträgliches Salz davon,
    wobei
    R9, R11, R12, R13, R14 und R15 für CH3 stehen; und
    (i) drei von R1, R2, R5 und R8 für OH stehen; und
    R17, R18 und einer von R1, R2, R5 und R8 gleich sind und ausgewählt sind aus der Gruppe bestehend aus O-Angeloyl, O-Senecioyl, O-4-Pentenoyl, O-Hexanoyl, O-2-Ethylbutyryl, O-Crotonoyl, O-Cinnamoyl und O-Benzoyl; oder
    (ii) R18 und drei von R1, R2, R5 und R8 für OH stehen; und
    R17 und einer von R1, R2, R5 und R8 gleich sind und ausgewählt sind aus der Gruppe bestehend aus O-Angeloyl, O-Senecioyl, O-4-Pentenoyl, O-Hexanoyl, O-2-Ethylbutyryl, O-Acetyl, O-Crotonoyl, O-Cinnamoyl und O-Benzoyl; oder
    (iii) R8 und zwei von R1, R2 und R5 für OH stehen;
    R17 für O-Tigloyl steht; und
    R18 und eines von R1, R2 und R5 gleich sind und ausgewählt sind aus der Gruppe bestehend aus O-Senecioyl, O-Crotonoyl, O-Acetyl, O-4-Pentenoyl, O-Hexanoyl, O-Cinnamoyl, O-Angeloyl und O-2-Ethylbutyryl; oder
    (iv) R5, R8, R18 und einer von R1 und R2 für OH stehen;
    R17 für O-Tigloyl steht; und
    einer von R1 und R2 ausgewählt ist aus der Gruppe bestehend aus O-Senecioyl, O-Crotonoyl, O-Acetyl, O-4-Pentenoyl, O-Hexanoyl, O-Cinnamoyl, O-Angeloyl und O-2-Ethylbutyryl.
  2. Die Verbindung nach Anspruch 1 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) drei von R1, R2, R5 und R8 für OH stehen; und
    R17, R18 und eines von R1, R2, R5 und R8 gleich sind und ausgewählt sind aus der Gruppe bestehend aus O-Angeloyl, O-Senecioyl, O-4-Pentenoyl, O-Hexanoyl, O-2-Ethylbutyryl, O-Crotonoyl, O-Cinnamoyl und O-Benzoyl; oder
    (ii) R18 und drei von R1, R2, R5 und R8 für OH stehen; und
    R17 und eines von R1, R2, R5 und R8 gleich sind und ausgewählt sind aus der Gruppe bestehend aus O-Angeloyl, O-Senecioyl, O-4-Pentenoyl, O-Hexanoyl, O-2-Ethylbutyryl, O-Acetyl, O-Crotonoyl, O-Cinnamoyl und O-Benzoyl.
  3. Die Verbindung nach Anspruch 2 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) R2, R5 und R8 für OH stehen; und
    R1, R17 und R18 gleich sind und ausgewählt sind aus der Gruppe bestehend aus O-Angeloyl, O-Senecioyl, O-4-Pentenoyl, O-Hexanoyl, O-2-Ethylbutyryl, O-Crotonoyl, O-Cinnamoyl und O-Benzoyl; oder
    (ii) R2, R5, R8 und R18 für OH stehen; und
    R1 und R17 gleich sind und ausgewählt sind aus der Gruppe bestehend aus O-Angeloyl, O-Senecioyl, O-4-Pentenoyl, O-Hexanoyl, O-2-Ethylbutyryl, O-Acetyl, O-Crotonoyl, O-Cinnamoyl und O-Benzoyl.
  4. Die Verbindung nach Anspruch 3 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) R2, R5 und R8 für OH stehen; und R1, R17 und R18 für O-Angeloyl stehen; oder
    (ii) R2, R5, R8 und R18 für OH stehen; und R1 und R17 für O-Angeloyl stehen.
  5. Die Verbindung nach Anspruch 3 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) R2, R5 und R8 für OH stehen; und R1, R17 und R18 für O-Senecioyl stehen; oder
    (ii) R2, R5, R8 und R18 für OH stehen; und R1 und R17 für O-Senecioyl stehen.
  6. Die Verbindung nach Anspruch 3 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) R2, R5 und R8 für OH stehen; und R1, R17 und R18 für O-Crotonoyl stehen; oder
    (ii) R2, R5, R8 und R18 für OH stehen; und R1 und R17 für O-Crotonoyl stehen.
  7. Die Verbindung nach Anspruch 3 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) R2, R5 und R8 für OH stehen; und R1, R17 und R18 für O-Cinnamoyl stehen; oder
    (ii) R2, R5, R8 und R18 für OH stehen; und R1 und R17 für O-Cinnamoyl stehen.
  8. Die Verbindung nach Anspruch 3 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) R2, R5 und R8 für OH stehen; und R1, R17 und R18 für O-4-Pentenoyl stehen; oder
    (ii) R2, R5, R8 und R18 für OH stehen; und R1 und R17 für O-4-Pentenoyl stehen.
  9. Die Verbindung nach Anspruch 3 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) R2, R5 und R8 für OH stehen; und R1, R17 und R18 für O-Hexanoyl stehen; oder
    (ii) R2, R5, R8 und R18 für OH stehen; und R1 und R17 für O-Hexanoyl stehen.
  10. Die Verbindung nach Anspruch 3 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) R2, R5 und R8 für OH stehen; und R1, R17 und R18 für O-2-Ethylbutyryl stehen; oder
    (ii) R2, R5, R8 und R18 für OH stehen; und R1 und R17 für O-2-Ethylbutyryl stehen.
  11. Die Verbindung nach Anspruch 3 oder ein pharmazeutisch verträgliches Salz davon, wobei
    (i) R2, R5 und R8 für OH stehen; und R1, R17 und R18 für O-Benzoyl stehen; oder
    (ii) R2, R5, R8 und R18 für OH stehen; und R1 und R17 für O-Benzoyl stehen.
  12. Die Verbindung nach einem der Ansprüche 1 bis 11 oder ein pharmazeutisch verträgliches Salz davon zur Verwendung als ein Medikament.
  13. Die Verbindung nach einem der Ansprüche 1 bis 11 oder ein pharmazeutisch verträgliches Salz davon zur Verwendung bei der Behandlung von Krebs; Hemmung des Krebswachstums, der Krebsinvasion, wobei der Krebs ausgewählt ist aus der Gruppe bestehend aus Brustkrebs, leukozytärem Krebs, Leberkrebs, Eierstockkrebs, Blasenkrebs, Prostatakrebs, Hautkrebs, Knochenkrebs, Hirnkrebs, Leukämiekrebs, Lungenkrebs, Dickdarmkrebs, ZNS-Krebs, Melanomkrebs, Nierenkrebs, Gebärmutterhalskrebs, Speiseröhrenkrebs, Hodenkrebs, Milzkrebs, Nierenkrebs, lymphatischem Krebs, Bauchspeicheldrüsenkrebs, Magenkrebs und Schilddrüsenkrebs.
  14. Eine Verbindung nach einem der Ansprüche 1 bis 11 oder ein pharmazeutisch verträgliches Salz davon zur Verwendung bei der Behandlung von Zelladhäsion, Zellanhaftung, Zellzirkulation; Hemmung von Viren; Vorbeugung von Hirnalterung; Verbesserung des Gedächtnisses; Verbesserung der Hirnfunktionen; Heilung von Enuresis, häufigem Urinieren, Harninkontinenz; Demenz, Alzheimer-Krankheit, Autismus, Hirntrauma, Parkinson-Krankheit oder anderen Krankheiten, die durch zerebrale Funktionsstörungen verursacht werden; Behandlung von Arthritis, Rheuma, schlechter Durchblutung, Arteriosklerose, Raynaud-Syndrom, Angina pectoris, Herzstörung, koronarer Herzkrankheit, Kopfschmerzen, Schwindel, Nierenerkrankung; zerebrovaskulärer Erkrankung; Hemmung der NF-Kappa B-Aktivierung; Behandlung von Hirnödemen, schwerem akutem Atemwegssyndrom, viralen Atemwegserkrankungen, chronischer venöser Insuffizienz, Bluthochdruck, chronischer Venenerkrankung, Ödemen, Entzündungen, Hämorrhoiden, peripherer Ödembildung, Krampfadererkrankung, Grippe, posttraumatischen Ödemen und postoperativen Schwellungen; Hemmung von Blutgerinnseln, Hemmung der Ethanolabsorption; Senkung des Blutzuckers oder Regulierung der Adrenocorticotropin- und Kortikosteronspiegel.
  15. Eine Zusammensetzung, umfassend eine wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 11 oder ein pharmazeutisch verträgliches Salz davon als ein Medikament.
EP17191658.8A 2010-07-16 2011-07-15 Neue oleanan-24-ester verbindungen zur behandlung von krebs und anderen krankheiten Active EP3301105B1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/US2010/042240 WO2011009032A1 (en) 2009-07-16 2010-07-16 Inhibiting the invasion and metastasis of cancer cells
US12/856,322 US8586719B2 (en) 2005-04-27 2010-08-13 Triterpenes for modulating gene expression and cell membrane, and as antiprotozoal agents
EP11807584.5A EP2593111B1 (de) 2010-07-16 2011-07-15 Neue verbindungen zur behandlung von krebs und anderen krankheiten
PCT/US2011/044233 WO2012009663A2 (en) 2010-07-16 2011-07-15 New compounds for treating cancer and other diseases

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP11807584.5A Division EP2593111B1 (de) 2010-07-16 2011-07-15 Neue verbindungen zur behandlung von krebs und anderen krankheiten

Publications (2)

Publication Number Publication Date
EP3301105A1 EP3301105A1 (de) 2018-04-04
EP3301105B1 true EP3301105B1 (de) 2020-04-15

Family

ID=45470102

Family Applications (2)

Application Number Title Priority Date Filing Date
EP17191658.8A Active EP3301105B1 (de) 2010-07-16 2011-07-15 Neue oleanan-24-ester verbindungen zur behandlung von krebs und anderen krankheiten
EP11807584.5A Active EP2593111B1 (de) 2010-07-16 2011-07-15 Neue verbindungen zur behandlung von krebs und anderen krankheiten

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP11807584.5A Active EP2593111B1 (de) 2010-07-16 2011-07-15 Neue verbindungen zur behandlung von krebs und anderen krankheiten

Country Status (8)

Country Link
EP (2) EP3301105B1 (de)
JP (2) JP6019021B2 (de)
KR (1) KR101960645B1 (de)
CN (7) CN106349317B (de)
AU (2) AU2011278983B2 (de)
CA (2) CA2805136C (de)
HK (1) HK1247207A1 (de)
WO (1) WO2012009663A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499577B2 (en) 2009-07-16 2016-11-22 Pacific Arrow Limited Natural and synthetic compounds for treating cancer and other diseases
EP3301105B1 (de) * 2010-07-16 2020-04-15 Pacific Arrow Limited Neue oleanan-24-ester verbindungen zur behandlung von krebs und anderen krankheiten
ES2666133T3 (es) * 2015-02-27 2018-05-03 Warszawski Uniwersytet Medyczny Derivado de protoescigenina, proceso de su preparación, uso de dicho compuesto y composición farmacéutica que comprende ese compuesto
CN107281203A (zh) * 2016-03-30 2017-10-24 南京惠宝生物医药有限公司 娑罗子提取物在制备防治老年痴呆药物中的应用
CN114209704A (zh) * 2021-12-21 2022-03-22 成都中医药大学 28-o-顺芷酰基匙羹藤新苷元在制备治疗肿瘤药物中的应用
CN116693591A (zh) * 2022-11-25 2023-09-05 大理大学 一个乌苏烷三萜咖啡酸酯化合物的制备与抗肿瘤应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5844662B2 (ja) * 1973-10-16 1983-10-04 塩野義製薬株式会社 １３，２８− エポキシオレアナンユウドウタイ ノ セイゾウホウ
MX9606493A (es) * 1994-06-24 1997-03-29 Nippon Shinyaku Co Ltd Derivado de triterpeno y composicion medicinal.
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
US6616943B2 (en) * 2001-08-31 2003-09-09 Fountain Silver Limited Composition comprising Wenguanguo extracts and methods for preparing same
US7488753B2 (en) 2003-10-09 2009-02-10 Pacific Arrow Limited Composition comprising triterpene saponins and compounds with angeloyl functional group, methods for preparing same and uses thereof
WO2008028060A2 (en) * 2006-09-01 2008-03-06 Pacific Arrow Limited Anti-tumor compounds for inhibiting cancer growth
US7262285B2 (en) * 2003-10-09 2007-08-28 Pacific Arrow Limited Anticancer biangeloyl saponins
WO2006029221A2 (en) * 2004-09-07 2006-03-16 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
US8614197B2 (en) * 2003-10-09 2013-12-24 Pacific Arrow Limited Anti-tumor compounds with angeloyl groups
TWI454269B (zh) * 2003-12-23 2014-10-01 Pacific Arrow Ltd 由文冠果（ｘａｎｔｈｏｃｅｒａｓ ｓｏｒｂｉｆｏｌｉａ）單離之化合物、其製備方法以及其用途
CN101123880B (zh) * 2004-09-07 2011-06-08 太平洋艾瑞有限公司 带有当归酰基的抗肿瘤化合物
CN101772511A (zh) * 2007-02-16 2010-07-07 太平洋艾瑞有限公司 通过影响粘连蛋白质表达阻止癌细胞的转移和新化合物及其应用
CN101998964B (zh) * 2008-02-15 2015-05-06 太平洋艾瑞有限公司 阻止癌细胞的转移的化合物及其应用
EP3301105B1 (de) * 2010-07-16 2020-04-15 Pacific Arrow Limited Neue oleanan-24-ester verbindungen zur behandlung von krebs und anderen krankheiten
JP7214409B2 (ja) 2018-09-05 2023-01-30 キヤノン株式会社 液体吐出ヘッド

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
JP2013541496A (ja) 2013-11-14
CN115197293A (zh) 2022-10-18
HK1247207A1 (zh) 2018-09-21
CN106905403B (zh) 2020-10-23
CN107519179B (zh) 2021-04-20
WO2012009663A2 (en) 2012-01-19
KR20180035244A (ko) 2018-04-05
CN107519179A (zh) 2017-12-29
CA2805136A1 (en) 2012-01-19
CN114671923A (zh) 2022-06-28
AU2011278983A1 (en) 2013-02-28
CA2805136C (en) 2021-06-08
EP2593111A2 (de) 2013-05-22
AU2011278983B2 (en) 2016-01-21
JP2017048195A (ja) 2017-03-09
CN106349317B (zh) 2020-08-25
CN103391776A (zh) 2013-11-13
WO2012009663A3 (en) 2013-08-08
CN106905403A (zh) 2017-06-30
CA3115431A1 (en) 2012-01-19
EP2593111A4 (de) 2014-07-23
CN103391776B (zh) 2023-11-28
AU2016202477A1 (en) 2017-11-02
CN106349317A (zh) 2017-01-25
EP3301105A1 (de) 2018-04-04
JP6019021B2 (ja) 2016-11-02
JP6549544B2 (ja) 2019-07-24
KR101960645B1 (ko) 2019-03-20
EP2593111B1 (de) 2017-09-27
CN114835771A (zh) 2022-08-02

Similar Documents

Publication Publication Date Title
US8785405B2 (en) Compounds for treating cancer and other diseases
WO2011009032A9 (en) Inhibiting the invasion and metastasis of cancer cells
US10214558B2 (en) Natural and synthetic compounds for treating cancer and other diseases
JP6549544B2 (ja) ガンおよび他の疾患を治療するための新規化合物
US9434677B2 (en) Natural and synthetic compounds for treating cancer and other diseases
US11485755B2 (en) Natural and synthetic compounds for treating cancer and other diseases
US10590163B2 (en) Natural and synthetic compounds for treating cancer and other diseases
Chen et al. Synthesis and cytotoxicity evaluation of 4′-amino-4′-dehydroxyloleandrin derivatives
KR100564383B1 (ko) 진세노사이드 유도체의 제조방법
US20230340012A1 (en) Natural and synthetic compounds for treating cancer and other diseases
KR101873607B1 (ko) 암 및 다른 질환들을 치료하기 위한 화합물
KR100547253B1 (ko) 암 예방 및 치료에 유효한 진세노사이드 유도체
US20230159436A1 (en) Applications of amide analogs of triterpenes in cures of cancer and other diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2593111

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1247207

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181001

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190521

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20191111

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2593111

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAK, MAY SUNG

Inventor name: CHAN, PUI-KWONG

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602011066344

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1257169

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200515

REG Reference to a national code

Ref country code: DE

Ref legal event code: R084

Ref document number: 602011066344

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200415

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200815

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200817

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200716

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1257169

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200715

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602011066344

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

26N No opposition filed

Effective date: 20210118

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200715

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200415

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20220624

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20220630

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20220701

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230706

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230703

Year of fee payment: 13

Ref country code: DE

Payment date: 20230703

Year of fee payment: 13

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230731

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230731